Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy

Canada NewsWire August 29, 2017

Investor Network: ProMetic Life Sciences Inc. to Host Earnings Call

Accesswire August 15, 2017

Prometic Reports 2017 Second Quarter Highlights and Financial Results

Canada NewsWire August 14, 2017

Prometic and Shenzhen Royal Asset Management Close Transaction for Joint Venture and Licensing Rights to PBI-4050, PBI-4547 and PBI-4425 in China

Canada NewsWire August 14, 2017

Prometic to Report its Second Quarter 2017 Financial Results and to Hold Conference Call / Webcast

Canada NewsWire August 8, 2017

Prometic Announces Positive Long Term Clinical Data on Ryplazym™ in Plasminogen Congenital Deficiency and Provides Regulatory Update

Canada NewsWire July 11, 2017

Prometic announces closing of equity offerings for aggregate gross proceeds of $61.7 million

Canada NewsWire July 6, 2017

Prometic Announces $53 Million Bought Deal Offering

Canada NewsWire June 15, 2017

New data presented by Prometic at ADA's Scientific Sessions validates PBI-4050's positive impact on kidneys in patients with diabetes and metabolic syndrome

PR Newswire June 12, 2017

Prometic Presents New Data on PBI-4050 and Plasminogen at the American Thoracic Society's 2017 International Conference

Canada NewsWire May 23, 2017

Prometic Reports 2017 First Quarter Highlights and Financial Results

Canada NewsWire May 15, 2017

Prometic reports its 2017 annual and special meeting of shareholders highlights

Canada NewsWire May 10, 2017

Prometic to Present New Data on how Plasminogen Reduces Acute Lung Injury at the American Thoracic Society's 2017 International Conference

Canada NewsWire May 8, 2017

Prometic Announces the Closing of the $25 Million Follow-On Financing From Structured Alpha LP, an Affiliate of Thomvest Asset Management Inc.

Canada NewsWire April 28, 2017

Prometic's PBI-4050 Shown to Reduce Liver Damage and Fibrosis in High-Fat Diet Induced Obesity and Metabolic Syndrome Mouse Model

PR Newswire April 20, 2017

Prometic Receives $9.5 Million Purchase Order From Multinational Client

Canada NewsWire April 7, 2017

Prometic completes the filing of its plasminogen Biologics License Application ("BLA") with the U.S. FDA

Canada NewsWire April 5, 2017

Prometic Reports its 2016 Fourth Quarter and Year End Highlights and Financial Results

Canada NewsWire March 30, 2017

Prometic and Shenzhen Royal Asset management (SRAM) to establish a joint venture to develop, manufacture and commercialize PBI-4050, PBI-4547 AND PBI-4425 in China

Canada NewsWire March 30, 2017

Prometic enters into binding agreement to secure $25 million follow-on financing from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.

Canada NewsWire March 24, 2017